Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Guidance & Regulatory Information

Guidance & Regulatory Information

                        Acts, Rules and Regulations
          Combination Products Guidance Documents
          Intercenter Consultative/ Collaborative Review Process
          Postmarketing Safety Reporting for Combination Products
          Genus v. FDA D.C. Circuit Court Decision and transition from drugs to devices Home
          Combination Products
          Guidance & Regulatory Information
          Postmarketing Safety Reporting for Combination ProductsGuidance & Regulatory Information Postmarketing Safety Reporting for Combination Products
  
  	
    Share
    Post
    Linkedin

    Email
    PrintThis page provides resources regarding the final rule on postmarketing safety reporting (PMSR) requirements for combination products that FDA issued on December 20, 2016 (81 FR 92603). The rule, as codified in 21 CFR 4, Subpart B, describes how to comply with PMSR requirements for combination products that have received FDA marketing authorization. Stakeholders with questions on PMSR requirements for combination products are encouraged to review these resources and, if you have questions, contact the Office of Combination Products at combination@fda.gov.

Regulations and Guidance

21 CFR 4, Subpart B.  Postmarketing Safety Reporting for Combination Products

Postmarketing Safety Reporting for Combination Products Guidance for Industry and FDA Staff

Compliance Policy

Combination Product Applicants should submit PMSRs according to the application-based PMSR requirements (21 CFR 4.102(c) and (d), 21 CFR 4.104(b)(1) and (b)(2)) and recordkeeping requirements (21 CFR 4.105(b)). Enforcement of these requirements went into effect on July 31, 2020 for Combination Product Applicants using the FDA Adverse Event Reporting System (FAERS) and Electronic Medical Device Reporting System (eMDR) to report ICSRs and on January 31, 2021 for Combination Product Applicants using the Vaccine Adverse Event Reporting System (VAERS) to report ICSRs.

See:

Compliance Policy for Combination Product Postmarketing Safety Reporting Immediately in Effect Guidance for Industry and FDA Staff

Adverse Event Electronic Reporting Systems

The adverse event electronic reporting systems, FDA Adverse Event Reporting System (FAERS), Electronic Medical Device Reporting System (eMDR), and Vaccine Adverse Event Reporting System (VAERS) have been updated to address combination product reporting considerations, including allowing Combination Product Applicants to satisfy multiple reporting requirements in a single report. For additional information, see the associated Technical Specifications:

FDA Adverse Event Reporting System (FAERS) Electronic Submissions

eMDR – Electronic Medical Device Reporting

Vaccine Adverse Event Reporting System (VAERS)

FDA welcomes comments from combination product reporters. Comments may be submitted to the Office of Combination Products, combination@fda.gov.

Combination Product PMSR Examples and Other Resources

The content included here is intended to assist combination product applicants in presenting certain combination product information in the data fields of postmarketing safety reporting systems (e.g., FAERS and eMDR)1
. FDA issued Federal Register notices describing a voluntary program for summary reporting of malfunctions available for certain device-led combination products.

Refer to Postmarketing Safety Reporting for Combination Products Guidance for Industry and FDA Staff (“PMSR Guidance”) for additional information. Reporters should refer to current technical specifications and other documents for detailed instructions for how to complete and submit ICSRs and other postmarketing safety reports.

**Example Scenarios.** Scenarios to illustrate how to report combination product information identified in sections V.B.2 and V.B.5 of the PMSR Guidance in the electronic reporting systems.  

	**NDA-approved prefilled on-body infusor (FAERS)**
		**BLA-approved product consisting of one vial of biological product along with three device constituent parts (FAERS)**
		**PMA-approved steroid-eluting lead (eMDR)**
		**Reporting for same or similar device constituent parts (FAERS)**
		**Field Alert Report for PMA-approved combination product (Form 3331a)**
	**Reporting Elements**. Identifies the data fields for the combination product information described in Section V.B.2 of the PMSR Guidance.
	**Device Product Codes (procodes).**Includes common procodes for device constituent parts of ANDA/NDA/BLA combination products.
	**Including Multiple Entities and/or Multiple Lot Numbers**. Illustrates how to submit information on more than one entity involved in the manufacture of the combination product and/or the specific lots of the constituent parts that comprise a combination product.Training and Outreach

Webinar on the Final Rule on Postmarketing Safety Reporting (PMSR) for Combination Products


1FDA has issued Federal Register (FR) notices describing a voluntary program for summary reporting of malfunctions, available for certain device-led combination products see https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems#malfunction.

                                                                                  Content current as of:
      07/23/2021Guidance & Regulatory Information

          
                        Acts, Rules and Regulations
          Combination Products Guidance Documents
          Intercenter Consultative/ Collaborative Review Process
          Postmarketing Safety Reporting for Combination Products
          Genus v. FDA D.C. Circuit Court Decision and transition from drugs to devices
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop